Inari Medical - NARI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $58.89
  • Forecasted Upside: 22.25%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$48.17
▼ -1.01 (-2.05%)

This chart shows the closing price for NARI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inari Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NARI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NARI

Analyst Price Target is $58.89
▲ +22.25% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Inari Medical in the last 3 months. The average price target is $58.89, with a high forecast of $74.00 and a low forecast of $47.00. The average price target represents a 22.25% upside from the last price of $48.17.

This chart shows the closing price for NARI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in Inari Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/8/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/6/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/2/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/2/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/31/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/29/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2024Truist FinancialBoost TargetHold ➝ Hold$46.00 ➝ $50.00
10/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$71.00 ➝ $74.00
10/29/2024Needham & Company LLCReiterated RatingHold
10/29/2024Piper SandlerBoost TargetNeutral ➝ Neutral$50.00 ➝ $52.00
10/29/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$66.00 ➝ $67.00
10/14/2024Truist FinancialLower TargetHold ➝ Hold$55.00 ➝ $46.00
10/9/2024Needham & Company LLCReiterated RatingHold
9/17/2024Stifel NicolausInitiated CoverageHold$50.00
9/3/2024Leerink PartnrsUpgradeHold
9/3/2024Leerink PartnersInitiated CoverageMarket Perform$47.00
8/26/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$50.00 ➝ $50.00
8/9/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy$68.00
7/31/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$84.00 ➝ $65.00
7/31/2024Truist FinancialReiterated RatingHold ➝ Hold$60.00 ➝ $55.00
7/31/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$55.00 ➝ $71.00
7/31/2024Robert W. BairdLower TargetOutperform ➝ Outperform$65.00 ➝ $63.00
7/31/2024Needham & Company LLCReiterated RatingHold
7/25/2024William BlairInitiated CoverageOutperform
7/18/2024Needham & Company LLCDowngradeBuy ➝ Hold
7/16/2024Truist FinancialBoost TargetHold ➝ Hold$47.00 ➝ $60.00
5/1/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$75.00 ➝ $55.00
5/1/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$100.00 ➝ $84.00
5/1/2024Piper SandlerLower TargetNeutral ➝ Neutral$55.00 ➝ $50.00
5/1/2024Needham & Company LLCLower TargetBuy ➝ Buy$72.00 ➝ $57.00
4/12/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$75.00
3/22/2024Truist FinancialLower TargetHold ➝ Hold$61.00 ➝ $52.00
3/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00
2/29/2024Truist FinancialReiterated RatingHold ➝ Hold$63.00 ➝ $61.00
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00
2/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$79.00 ➝ $75.00
2/29/2024Piper SandlerDowngradeOverweight ➝ Neutral$85.00 ➝ $55.00
1/23/2024Needham & Company LLCInitiated CoverageBuy$72.00
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$65.00 ➝ $70.00
11/3/2023Truist FinancialBoost TargetHold ➝ Hold$60.00 ➝ $65.00
11/2/2023Piper SandlerLower TargetOverweight ➝ Overweight$90.00 ➝ $85.00
8/3/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$83.00
8/3/2023Piper SandlerLower Target$92.00 ➝ $90.00
8/3/2023Wells Fargo & CompanyLower Target$105.00 ➝ $100.00
7/19/2023Truist FinancialLower TargetHold$70.00 ➝ $65.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$79.00
4/18/2023Truist FinancialBoost Target$68.00 ➝ $70.00
2/28/2023Canaccord Genuity GroupBoost TargetBuy$77.00 ➝ $80.00
2/21/2023Canaccord Genuity GroupBoost TargetBuy$76.00 ➝ $77.00
1/31/2023Truist FinancialLower TargetHold$75.00 ➝ $65.00
1/6/2023Morgan StanleyLower TargetOverweight$95.00 ➝ $83.00
12/20/2022Truist FinancialLower TargetHold$84.00 ➝ $75.00
11/3/2022Morgan StanleyBoost TargetOverweight$93.00 ➝ $95.00
11/3/2022Wells Fargo & CompanyLower Target$125.00 ➝ $105.00
10/17/2022Truist FinancialLower TargetHold$87.00 ➝ $80.00
10/17/2022BTIG ResearchLower TargetBuy$100.00 ➝ $97.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$88.00
9/29/2022Berenberg BankInitiated CoverageBuy$85.00
9/16/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$92.00 ➝ $94.00
9/12/2022Truist FinancialInitiated CoverageHold$87.00
7/15/2022Morgan StanleyLower TargetOverweight$108.00 ➝ $93.00
6/24/2022BTIG ResearchLower TargetBuy$130.00 ➝ $100.00
6/21/2022Piper SandlerInitiated CoverageOverweight$100.00
3/23/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
3/14/2022Canaccord Genuity GroupLower TargetBuy$102.00 ➝ $96.00
2/24/2022Morgan StanleyLower TargetOverweight$119.00 ➝ $108.00
2/24/2022Leerink PartnersBoost TargetOutperform$85.00 ➝ $95.00
11/29/2021BTIG ResearchReiterated RatingBuy$139.00
11/10/2021Leerink PartnersBoost TargetOutperform$110.00 ➝ $120.00
8/11/2021Leerink PartnersLower TargetOutperform$126.00 ➝ $110.00
5/12/2021Morgan StanleyBoost TargetOverweight$126.00 ➝ $129.00
3/10/2021Leerink PartnersBoost TargetOutperform$116.00 ➝ $126.00
3/10/2021Wells Fargo & CompanyBoost TargetOverweight$112.00 ➝ $125.00
3/10/2021Morgan StanleyBoost TargetOverweight$85.00 ➝ $126.00
3/10/2021BTIG ResearchBoost TargetBuy$125.00 ➝ $135.00
1/21/2021BTIG ResearchBoost TargetBuy$92.00 ➝ $110.00
1/20/2021Wells Fargo & CompanyBoost TargetOverweight$79.00 ➝ $112.00
12/15/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$79.00
11/18/2020BTIG ResearchInitiated CoverageBuy$92.00
11/13/2020Morgan StanleyBoost TargetOverweight$76.00 ➝ $85.00
11/13/2020Leerink PartnersBoost TargetOutperform$80.00 ➝ $90.00
10/29/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $76.00
9/28/2020Leerink PartnersInitiated CoverageOutperform$80.00
8/12/2020Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $66.00
6/16/2020Bank of AmericaInitiated CoverageNeutral$56.00
6/16/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$49.00
6/16/2020Morgan StanleyInitiated CoverageEqual Weight$52.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/3/2024
  • 11 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/3/2024
  • 21 very positive mentions
  • 44 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
6/2/2024
  • 7 very positive mentions
  • 87 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 20 very positive mentions
  • 45 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/1/2024
  • 8 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/31/2024
  • 18 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 14 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 14 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Inari Medical logo
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $48.17
Low: $47.95
High: $50.29

50 Day Range

MA: $43.51
Low: $40.62
High: $49.18

52 Week Range

Now: $48.17
Low: $36.73
High: $67.13

Volume

439,322 shs

Average Volume

1,001,537 shs

Market Capitalization

$2.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Inari Medical?

The following sell-side analysts have issued stock ratings on Inari Medical in the last year: Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, Leerink Partners, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, Truist Financial Co., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for NARI.

What is the current price target for Inari Medical?

9 Wall Street analysts have set twelve-month price targets for Inari Medical in the last year. Their average twelve-month price target is $58.89, suggesting a possible upside of 22.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting NARI will reach $74.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $47.00 for Inari Medical in the next year.
View the latest price targets for NARI.

What is the current consensus analyst rating for Inari Medical?

Inari Medical currently has 6 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NARI, but not buy more shares or sell existing shares.
View the latest ratings for NARI.

What other companies compete with Inari Medical?

How do I contact Inari Medical's investor relations team?

Inari Medical's physical mailing address is 9 Parker Suite 100, Irvine CA, 92618. The company's listed phone number is 877-923-4747 and its investor relations email address is [email protected]. The official website for Inari Medical is www.inarimedical.com. Learn More about contacing Inari Medical investor relations.